Credit Suisse Group reaffirmed their hold rating on shares of Spark Therapeutics (NASDAQ:ONCE) in a report published on Friday. They currently have a $44.00 target price on the biotechnology company’s stock.
Other equities analysts have also issued reports about the stock. Cantor Fitzgerald reiterated an overweight rating and issued a $80.00 target price (down from $103.00) on shares of Spark Therapeutics in a report on Thursday, January 10th. Zacks Investment Research lowered shares of Spark Therapeutics from a buy rating to a hold rating in a report on Saturday, October 13th. B. Riley upgraded shares of Spark Therapeutics from a neutral rating to a buy rating and upped their price objective for the stock from $68.00 to $71.00 in a report on Wednesday, November 7th. Raymond James restated a buy rating on shares of Spark Therapeutics in a report on Monday, November 26th. Finally, Mizuho decreased their price objective on shares of Spark Therapeutics to $62.00 and set a buy rating on the stock in a report on Wednesday, November 7th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company. Spark Therapeutics presently has a consensus rating of Buy and an average price target of $65.20.
ONCE opened at $47.44 on Friday. The stock has a market cap of $1.79 billion, a P/E ratio of -6.22 and a beta of 2.06. Spark Therapeutics has a twelve month low of $34.53 and a twelve month high of $96.59. The company has a current ratio of 10.71, a quick ratio of 10.36 and a debt-to-equity ratio of 0.09.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.
Recommended Story: Why is the ROA ratio important?
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.